Concepedia

Caroline Almon

CA

Statistics

Publications

6

Citations

384

H-Index

6

Active since

2017

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Massachusetts General Hospital

Agios Pharmaceuticals (United States)

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

Caroline Almon is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, hematologic malignancy therapy, and oncology.

Publications per year

2017–2025

6

Publications

6

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2020 · 233 citations · Full text

, , +9

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2018 · 61 citations

, , +13

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial

Mrinal M. Gounder, Melissa L. Johnson, Rebecca S. Heist et al. · Nature Communications · 2025 · 34 citations · Full text

, , +14

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Eytan M. Stein, Courtney D. DiNardo, Alice S. Mims et al. · Blood · 2017 · 25 citations

, , +11

Preliminary Results from a Phase 1 Dose Escalation Study of FHD-286, a Novel BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, Administered As an Oral Monotherapy in Patients with Advanced Hematologic Malignancies

Courtney D. DiNardo, Michael R. Savona, Ashwin Kishtagari et al. · Blood · 2023 · 21 citations

, , +12

1–5 of 6